MetLife Investment Management’s Janux Therapeutics JANX Stock Holding History

MetLife Investment Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$362K	Buy	26,031 +2,155	+9%	+$29.5K	﹤0.01%	1912
2025 Q4	$329K	Hold	23,876	–	–	﹤0.01%	2007
2025 Q3	$584K	Hold	23,876	–	–	﹤0.01%	1729
2025 Q2	$552K	Buy	23,876 +5,213	+28%	+$137K	﹤0.01%	1628
2025 Q1	$504K	Buy	18,663 +1,365	+8%	+$51.5K	﹤0.01%	1724
2024 Q4	$926K	Buy	17,298 +949	+6%	+$50.2K	0.01%	1455
2024 Q3	$743K	Hold	16,349	–	–	﹤0.01%	1564
2024 Q2	$685K	Buy	16,349 +7,288	+80%	+$342K	﹤0.01%	1546
2024 Q1	$341K	Sell	9,061 -1,553	-15%	-$33.8K	﹤0.01%	1900
2023 Q4	$114K	Hold	10,614	–	–	﹤0.01%	2542
2023 Q3	$107K	Hold	10,614	–	–	﹤0.01%	2545
2023 Q2	$126K	Hold	10,614	–	–	﹤0.01%	2547
2023 Q1	$128K	Hold	10,614	–	–	﹤0.01%	2452
2022 Q4	$140K	Hold	10,614	–	–	﹤0.01%	2447
2022 Q3	$144K	Hold	10,614	–	–	﹤0.01%	2485
2022 Q2	$130K	Hold	10,614	–	–	﹤0.01%	2589
2022 Q1	$152K	Buy	10,614 +5,312	+100%	+$86.9K	﹤0.01%	2509
2021 Q4	$105K	Hold	5,302	–	–	﹤0.01%	2392
2021 Q3	$115K	Buy	+5,302	New	+$153K	﹤0.01%	2380

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MetLife Investment Management's JANX Position: Q1 2026 in Review

MetLife Investment Management increased its Janux Therapeutics (JANX) stake by 9% in Q1 2026, buying an estimated $29.5K and bringing the position to 26,031 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

MetLife Investment Management first reported a position in JANX in Q3 2021 and has held it in 19 quarters since. The position peaked at $926K in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

MetLife Investment Management held 26,031 shares of Janux Therapeutics worth $362K as of Q1 2026.
MetLife Investment Management bought 2,155 Janux Therapeutics shares in Q1 2026, an estimated $29.5K.
Janux Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1912 holding.
MetLife Investment Management first reported a position in Janux Therapeutics in Q3 2021 and has held it in 19 quarters since.
MetLife Investment Management's Janux Therapeutics position peaked at $926K in Q4 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.